Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Controlling Gas Liquid Chemistries

Published: Monday, January 21, 2013
Last Updated: Monday, January 21, 2013
Bookmark and Share
Sygnature Discovery has reported results demonstrating how the Uniqsis FlowSyn™ flow reactor system allows them to perform traditionally hazardous chemistries in a controlled manner.

For example, using the proprietary FlowSyn technology with a Uniqsis GAM IIgas-liquid reactor, laboratory scientists at Sygnature Discovery, in conjunction with Uniqsis, have developed high pressure reaction protocols that have enabled them to reproducibly perform carbonylation chemistries under continuous flow through conditions.

Dr Daniel Hamza, a senior research chemist at Sygnature Discovery commented "The option to use a gas addition module has opened up a multitude of gas-liquid reaction chemistries that we can perform using our FlowSy nsystem". He added "The FlowSyn is a straightforward and robust piece of kit to operate. The ability to add on new reactors to the existing set-up is of particular benefit since the latest technology can be easily incorporated into our synthetic plans". In conclusion Dr Hamza said "Flow chemistry offers many advantages over traditional batch processing methods notably better reproducibility and scalability as well as enhanced safety, particularly with hazardous reactions such as nitration and carbonylation".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sygnature Discovery’s Group Invests in New Start Up, Peak Proteins
Investment is part of an ongoing strategy to build and expand the Group’s extensive capabilities.
Thursday, January 28, 2016
Sygnature Discovery Strengthens Team with Three Key Appointments
Company appoints Dr Tim Schulz-Utermoehl, Dr Martin Quibell and Dr Scott Pollack.
Saturday, January 31, 2015
Sygnature Discovery and Proteros Biostructures Establish Strategic Alliance
Under the terms of the agreement, Sygnature and Proteros will collaborate to provide integrated services to advance clients’ drug discovery projects.
Wednesday, October 23, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!